New approach in Understanding Colorectal Cancer Immunosuppression and Immunotherapy-Based Strategies in the Treatment of Microsatellite Stable Colorectal Cancer

1 Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14(2):89-103. Search in Google Scholar

2 Goodla L, Xue X. The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis. Cells. 2022; 11(15):2313. Search in Google Scholar

3 Bhat AA, Nisar S, Singh M et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond). 2022; 42(8):689-715. Search in Google Scholar

4 Lucas C, Barnich N, Nguyen HTT. Microblota, Inflammatlon and Colorectal Cancer. Int J Mol Sci. 2017; 18(6):1310. Search in Google Scholar

5 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. Search in Google Scholar

6 Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014; 20(29):9872-81. Search in Google Scholar

7 Borowczak J, Szczerbowski K, Maniewski M, et al. The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma-Recent Findings and Review. Biomedicines. 2022; 10(7): 1670. Search in Google Scholar

8 Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science. 2013; 339(6117):286-91. Search in Google Scholar

9 Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019; 25(31):4383-4404. Search in Google Scholar

10 Gulubova MV, Chonov DC, Ivanova KV, et al. Intratumoural expression of IL-6/STAT3, IL-17 and FOXP3 immune cells in the mmunosuppressive tumour microenvironment of colorectal cancer. Immune cells-positive for IL-6,STAT3, IL-17 and FOXP3 and colorectal cancer development. Biotechnol Biotechnological Equipment, 2022; 36:1, 327-338, DOI: 10.1080/13102818.2022.2072765 Search in Google Scholar

11 De Simone V, Franzè E, Ronchetti G, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015; 34(27):3493-503. Search in Google Scholar

12 Kitamura H, Ohno Y, Toyoshima Y, et al. lnterleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017; 108(10): 1947-1952. Search in Google Scholar

13 Lin Y, He Z, Ye J, et al. Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer. Onco Targets Ther. 2020; 13:13023-13032. Search in Google Scholar

14 Rossi JF, Negrier S, James ND, etal. A phase l/ll study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010; 103:1154-1162. Search in Google Scholar

15 Puchalski T, Prabhakar U, Jiao Q, et al. Pharmacokinetic and pharmacodynamics modeling of an anti-inteleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16:1652-1661. Search in Google Scholar

16 Li J, Xu J, Yan X, et al. Targeting lnterleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Med Sci Monit. 2018; 24:5501-5508. Search in Google Scholar

17 Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40:1830-1835. Search in Google Scholar

18 Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 2016. https://di.org/10.1136/gutjnl-2016-311585 Search in Google Scholar

19 Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015; 26(10):2141-9. Search in Google Scholar

20 Zhang Y, Rajput A, Jin N, et al. Mechanisms of Immunosuppression in Colorectal Cancer. Cancers (Basel). 2020; 12(12):3850. Search in Google Scholar

21 Velikova TV, Miteva L, Stanilov N, et al. lnterleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2020; 26(16):1912-1925. Search in Google Scholar

22 Tseng-Rogenski SS, Hamaya Y, Choi DY, et al. Interteukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology. 2015; 148(3):579-89. Search in Google Scholar

23 Grivennikov SI, Wang Κ, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012; 491(7423):254-8. Search in Google Scholar

24 Chung L, Thiele Orberg E, Geis AL, et al. Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe. 2018; 23(2):203-214.e5. Search in Google Scholar

25 Lin Y, Xu J, Su H, et al. lnterleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol. 2015; 17(1):50-6. Search in Google Scholar

26 Pan B, Shen J, Cao J, et al. lnterleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015; 5:16053. doi: Search in Google Scholar

27 Cui G, Li Z, Florholmen J, et al. Dynamic stromal cellular reaction throughout human colorectal adenoma-carcinoma sequence: A role of TH17/IL-17A. Biomed Pharmacother. 2021; 140:111761. Search in Google Scholar

28 Tong Z, Yang XO, Yan H, et al. A protective role by interleukin 17F in colon tumorigenesis. PLoS One. 2012; 7(4):e34959. Search in Google Scholar

29 Hurtado CG, Wan F, Housseau F, et al. Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer. Gastroenterology. 2018 Dec; 155(6):1706-1715. Search in Google Scholar

30 Li X, Wang Y, Han C, et al. Colorectal cancer progression is associated with accumulation of Th17 lymphocytes in tumor tissues and increased serum levels of interleukin-6. Tohoku J Exp Med. 2014; 233(3):175-82. Search in Google Scholar

31 Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009; 27(2):186-92. Search in Google Scholar

32 Frey DM, Droeser RA, Viehl CT, et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells prediets improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010; 126(11):2635-43. Search in Google Scholar

33 Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 2011; 60(7):909-18. Search in Google Scholar

34 Xu P, Fan W, Zhang Z, et al. The Clinicopathological and Prognostic Implications of FoxP3+ Regulatory T Cells in Patients with Colorectal Cancer: A Meta-Analysis. Front Physiol. 2017; 8:950. Search in Google Scholar

35 Cavalleri T, Bianchi P, Basso G, et al. Alleanza contro il Cancro (ACC) Colorectal Cancer Working Group. Combined Low Densities of FoxP3+ and CD3+ Tumor-infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunol Res. 2019; 7(5):751-758. Search in Google Scholar

36 Rezalotfi A, Ahmadian E, Aazami H, et al. Gastric Cancer Stem Cells Effect on Th17/Treg Balance; A Bench to Beside Perspective. Front Oncol. 2019; 9:226. Search in Google Scholar

37 Aristin Revilla S, Kranenburg Ο, Coffer PJ. Colorectal Cancer-lnfiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front Immunol. 2022; 13:903564. Search in Google Scholar

38 Kuwahara T, Hazama S, Suzuki N, et al. Intratumoural-infiltrating CD4+and FOXP3+T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019; 121(8):659-665. Search in Google Scholar

39 Llosa NJ, Luber B, Tarn AJ, et al. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clin Cancer Res. 2019; 25(17):5250-5259. Search in Google Scholar

40 Willis JA, Overman MJ, Vilar E. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res. 2019;25(17):5185-5187. Search in Google Scholar

41 Liu C, Liu R, Wang Β, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021 ;9(1):e001895. Search in Google Scholar

42 André T, Cohen R, Salem ME. Immune Checkpoint Blockade Therapy in Patients with Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. Am Soc Clin Oncol Educ Book. 2022a;42:1-9. Search in Google Scholar

43 Svrcek M, Lascols O, Cohen R, et al. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other Sites: Differences between tumors. Bull Cancer. 2019;106(2):119-128. Search in Google Scholar

44 André T, Lonardi S, Wong KYM, et al. Nivolumab plus lowdose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022b;33(10):1052-1060. Search in Google Scholar

45 Guyot D'Asnières De Salins A, Tachon G, Cohen R, et al. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open. 2021;6(3):100120. Search in Google Scholar

46 Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-375. Search in Google Scholar

47 Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Ν Engl J Med. 2004;350(23):2335-42. Search in Google Scholar

48 Tabernero J, Yoshino T, Cohn AL, et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508. Search in Google Scholar

49 Baran B, Ozupek NM, Tetik NY, et al. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res 2018;11(4): 264-273. Search in Google Scholar

50 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol. 2010; 17 Suppl 1(Suppl 1):S3-17. Search in Google Scholar

51 Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17(4):258-273. Search in Google Scholar

52 Wilkinson K, Ng W, Roberts TL, et al. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer. J Clin Pathol. 2021;74(10):625-634. Search in Google Scholar

53 Talaat IM, Elemam NM, Zaher S, et al. Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Front Med (Lausanne). 2022;9:955599. Search in Google Scholar

54 Jacobs J, Smits E, Lardon F, et al. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res. 2015;2015:158038. Search in Google Scholar

55 André T, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. Ν Engl J Med. 2020;383(23):2207-2218. Search in Google Scholar

56 Huyghe N, Benidovskaya E, Stevens Ρ, et al. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers (Basel). 2022;14(9):2241. Search in Google Scholar

57 Moroney JW, Powderly J, Lieu CH, et al. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020;26(21):5631-5637. Search in Google Scholar

58 Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. Search in Google Scholar

59 Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-6. Search in Google Scholar

60 Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 Jan 10;40(2):161-170. doi: 10.1200/JCO.21.01015. Epub 2021 Oct 12. PMID: 34637336. Search in Google Scholar

61 Gong J, Wang C, Lee PP, et al. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. J Natl Compr Canc Netw. 2017;15(2):142-147. Search in Google Scholar

62 Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1(3):207-216. Search in Google Scholar

63 Baraibar I, Mirallas Ο, Saoudi Ν, et al. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel). 2021;13(24):6311. Search in Google Scholar

64 Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052-61. Search in Google Scholar

65 Di Biasio S, Wortel IM, van Bladel DA, et al. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016;5(8):e1192739. Search in Google Scholar

66 Galaine J, Turco C, Vauchy C, et al. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. Int J Cancer. 2019;145(11):3112-3125. Search in Google Scholar

67 Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015;3(9):1052-62. Search in Google Scholar

68 Cremolini C, Antoniotti C, Rossini D, et al. GONO Foundation Investigatore. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497-507. Search in Google Scholar

69 Tabernero J, Grothey A, Arnold D, et al. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. ESMO Open. 2022;7(5): 100559. Search in Google Scholar

70 Wang W, Wu L, Zhang J, et al. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animai model. Biochem Biophys Res Commun. 2017;487(1):1-7. Search in Google Scholar

71 Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. Search in Google Scholar

72 Segal NH, Cercek A, Ku G, et al. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clin Cancer Res. 2021 ;27(8):2200-2208. Search in Google Scholar

73 Vanpouille-Box C, Formenti SC, Demaria S. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clin Cancer Res. 2018;24(2):259-265. Search in Google Scholar

74 D'Souza WN, Chang CF, Fischer AM, et al. The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol. 2008; 181(11)7617-29. Search in Google Scholar

75 Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217-223. Search in Google Scholar

76 Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Ν Engl J Med. 2019;381 (17): 1632-1643. Search in Google Scholar

77 Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD1, PD-L1, and CTLA4. Clin Cancer Res. 2015;21(7):1639-51. Search in Google Scholar

78 Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585-608. Search in Google Scholar

79 Osada T, Patel SP, Hammond SA, et al. CEA/CD3 bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64(6):677-88. Search in Google Scholar

80 Caballero-Baños M, Benitez-Ribas D, Tabera J, et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016;64:167-74. Search in Google Scholar

81 Chon HJ, Kim H, Noh JH, et al. STING signaling is a potential immunotherapeutic target in colorectal cancer. J Cancer. 2019;10(20):4932-4938. Search in Google Scholar

82 Geevarghese SK, Geller DA, de Haan HA, et al. Phase l/ll study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21(9):1119-28. Search in Google Scholar